Myeloma clinical trials at UCSF
1 research study open to eligible people
Myeloma is a cancer that starts in plasma cells in the bone marrow. UCSF is recruiting for trials to explore new treatments for myeloma patients with relapsed or refractory disease. One of these trials is looking at a new MMSET inhibitor.
MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
open to eligible people ages 18 years and up
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
San Francisco, California and other locations
Our lead scientists for Myeloma research studies include Alfred Chung, MD.
Last updated: